

Contents

Subjects	Page
List of abbreviations.....	II
List of Figures.....	VII
List of Tables.....	IX
• Introduction	1
• Aim of the Study	8
• Review of Literature	
♦ Chapter (1): Budd Chiari Syndrome	9
♦ Chapter (2): Prognosis and Survival of BCS Patients	64
• Patients and Methods	88
• Results	96
• Discussion	130
• Conclusion	147
• Recommendation	149
• Summary	150
• References	154
• Arabic Summary	

List of Abbreviations

Abbrev.	Meaning
ACAs	Anticardiolipin Antibodies
ACL IgG	Anticardiolipin IgG
ACL IgM	Anticardiolipin IgM
AFP	Alpha feto protein
ALB	Albumin
ALP	Alkaline phosphatase
ALT	Alanin amino-transferase
ANA	Anti nuclear antibody
Anti DNA	Anti double stranded DNA
APAs	Antiphospholipid antibodies
APC	Activated protein C
APCR	Activated protein C resistance
APS	Antiphospholipid syndrome
APTT	Activated partial thromboplastin time
AST	Aspartate amino-transferase
AUC	Area under curve
AT III	Antithrombin III
BCS	Budd-Chiari syndrome

List of Abbreviations

BD	Behcet Disease
BM	Bone marrow
BUN	Blood urea nitrogen
CD	Cluster of differentiation
CML	Chronic Myelogenous leukemia
CALR	Calreticulin
CT	Computed Tomography
DB	Direct bilirubin
DIC	Disseminated intravascular coagulation
DVT	Deep venous thrombosis
EASL	European Association for the study of liver diseases
EPO	Erythropoietin
ESR	Erythrocyte sedimentation rate
ET	Essential thrombocythemia
FVLM	Factor V Leiden mutation
HA	Hepatic artery
Hb	Hemoglobin
HCC	Hepatocellular carcinoma
HcT	Hematocrit
HH	Hyperhomocysteinemia

List of Abbreviations

HVs	Hepatic veins
INR	International normalized ratio
IVC	Inferior vena cava
JAK2	Janus tyrosine kinase-2
LA	Lupus Anticoagulant
LFTs	Liver function tests
LHV	Left hepatic vein
LMWH	Low molecular weight heparin
MELD	Model for End stage Liver Disease
MDS	Myelodysplastic syndromes
MF	Myelofibrosis
MHV	Middle hepatic vein
MPDs	Myeloproliferative disorders
MPN	Myeloproliferative neoplasia
MRI	Magnetic resonance imaging
MRV	Magnetic resonance venography
MSCT	Multislice CT
MTHFR	Methylenetetrahydro-folate reductase
OCPs	Oral Contraceptive Pills
PC	Protein C
PCR	Polymerase chain reaction

List of Abbreviations

PGM	Prothrombin gene mutation
PHG	Portal hypertensive gastropathy
PIs	Prognostic indices
PLT	Platelets
PMF	Primary myelofibrosis
PNH	Paroxysmal nocturnal hemoglobinuria
PS	Protein S
PT	Prothrombin time
PTFE	Polytetrafluoroethylene
PTT	Partial thromboplastin time
PV	Portal vein
PVT	Portal vein thrombosis
RHV	Right hepatic vein
ROC	Reciever Operating Curve
SAAG	Serum-ascites albumin gradient
SD	Standard deviation
SE	Secndry erythrocytosis
SLE	Systemic lupus erythematosus
STAT	Signal transducer and activator of transcription
SVT	Splanchnic vein thrombosis

List of Abbreviations

TB	Total bilirubin
TIPS	Transjugular Intrahepatic Portosystemic Shunt
UNOS	United Network for Organ Sharing
VKA	Vitamin K antagonists
VOD	Veno-occlusive disease
VTE	Venous thromboembolism
WBCs	White blood cells
WHO	World Health Organization

List of Figures

<u>No.</u>	<u>Figure</u>	<u>Page</u>
<u>1</u>	A diagnostic algorithm for CML, polycythemia vera, essential thrombocythemia and primary myelofibrosis.	22
<u>2</u>	Occlusion of upper part of IVC.	38
<u>3</u>	CT in a 28-year-old female with idiopathic acute Budd-Chiari syndrome demonstrates hepatomegaly with diffuse patchy enhancement due to hepatic congestion and necrosis.	39
<u>4</u>	A 42-year-old female patient with chronic Budd-Chiari syndrome demonstrates large enhancing regenerative nodule (arrow) as well as ascites and lack of hepatic opacification due to congestion and necrosis.	41
<u>5</u>	Short segment obstruction in inferior vena cava.	42
<u>6</u>	Collateral veins in Budd-Chiari syndrome.	43
<u>7</u>	Proposed management strategy of BCS.	57
<u>8</u>	Proposed algorithm for the management of hepatic nodules in BCS patients.	60
<u>9</u>	Survival curves of patients with Budd-Chiari syndrome from different time periods.	82
<u>10</u>	Distribution of the studied patients according to their residence.	97
<u>11</u>	Different aetiological factors of BCS in both groups.	99
<u>12</u>	Complications of interventions (group I).	102
<u>13</u>	Child and Rotterdam classes in the studied patients.	103

<u>No.</u>	<u>Figure</u>	<u>Page</u>
<u>14</u>	Shows one year survival function (time to death) of the included patients (Kaplan-Meier).	104
<u>15</u>	One year survival curves before and after 2010.	106
<u>16</u>	Three year survival curves before and after 2010.	107
<u>17</u>	Shows the difference in three year survival curves of intervention and non-intervention groups before 2010.	109
<u>18</u>	Shows the difference in three year survival curves of intervention and non-intervention groups after 2010.	110
<u>19</u>	Five year survival curves before and after 2010.	112
<u>20</u>	Shows the difference in five year survival curves of intervention and non-intervention groups before 2010.	113
<u>21</u>	Shows the difference in five year survival curves of intervention and non-intervention groups after 2010.	115
<u>22</u>	Validity of different prognostic indices for prediction of one year survival.	122
<u>23</u>	Validity of BCS-TIPS score for prediction of one year survival among patients underwent TIPS.	124
<u>24</u>	Validity of different prognostic indices for prediction of one year shunt patency.	129

List of Tables

<u>No.</u>	<u>Table</u>	<u>Page</u>
<u>1</u>	Sites of venous obstruction in BCS	10
<u>2</u>	Classification of BCS according to the site of venous obstruction.	11
<u>3</u>	Causes of BCS.	15
<u>4</u>	French-American-British (FAB) and World Health Organization (WHO) classification of MPDs.	20
<u>5</u>	The relative risks of common thrombophilic conditions.	26
<u>6</u>	Comparison of the prevalence of the etiological factors of BCS in Egypt.	28
<u>7</u>	The laboratory work-up for BCS.	31
<u>8</u>	Indications for TIPS.	53
<u>9</u>	Contraindications for Placement of TIPS.	53
<u>10</u>	(Rotterdam) Murad's Budd–Chiari syndrome prognostic classification.	79
<u>11</u>	Different prognostic scores and their implications.	84
<u>12</u>	Demographic data of the studied patients.	96
<u>13</u>	Clinical data of studied patients.	98
<u>14</u>	Laboratory investigations of studied patients.	99
<u>15</u>	Doppler findings in the studied patients.	100
<u>16</u>	Comparison between group I and II regarding Doppler findings of Liver related veins.	100
<u>17</u>	Intervention issues (types of interventions & stents, stent revision).	101

List of Tables

<u>No.</u>	<u>Table</u>	<u>Page</u>
<u>18</u>	Different prognostic scores in the included patients.	103
<u>19</u>	Global survival rates and one year shunt patency (TIPS).	104
<u>20</u>	One year survival rates.	105
<u>21</u>	Means for survival time regarding one year before and after 2010.	105
<u>22</u>	Three years survival rate.	106
<u>23</u>	Mean survival time before and after 2010.	107
<u>24</u>	Three year survival rates before 2010 according to intervention.	108
<u>25</u>	Means for survival time regarding three years before 2010.	108
<u>26</u>	Three year survival rates after 2010 according to intervention.	109
<u>27</u>	Means for survival time regarding three years after 2010.	110
<u>28</u>	Five years survival rates.	111
<u>29</u>	Mean and median survival time before and after 2010 regarding 5 year survival.	111
<u>30</u>	Five year survival rates according to intervention before 2010.	112
<u>31</u>	Means and medians for survival time regarding five years before 2010.	113
<u>32</u>	Five year survival rates according to intervention after 2010.	114
<u>33</u>	Means and medians for survival time regarding five years after 2010.	114

<u>No.</u>	<u>Table</u>	<u>Page</u>
<u>34</u>	Relation between demographic factors and one year survival rate.	116
<u>35</u>	Relation between clinical data and one year survival rate.	117
<u>36</u>	Relation between laboratory investigations and one year survival rate.	118
<u>37</u>	Relation between etiology and one year survival rate.	119
<u>38</u>	Relation between abdominal Doppler findings and one year survival rate.	120
<u>39</u>	Relation between intervention and one year survival rate.	120
<u>40</u>	Relation between most common complications of intervention and one year survival rate (among intervention group).	121
<u>41</u>	Relation between different prognostic indices and one year survival rate.	122
<u>42</u>	Area Under the Curve of PIs.	123
<u>43</u>	Cut off values, sensitivity and specificity of PIs.	123
<u>44</u>	BCS-TIPS score best cut off value, sensitivity, specificity and Area Under the Curve.	125
<u>45</u>	Logistic regression analysis for factors affecting one year survival.	126
<u>46</u>	Relation between demographic factors and one year shunt patency.	127
<u>47</u>	Relation between etiology and one year shunt patency.	127
<u>48</u>	Relation between the most common complications of intervention and one year shunt patency.	128

List of Tables

<u>No.</u>	<u>Table</u>	<u>Page</u>
<u>49</u>	Relation between different prognostic indices and one year shunt patency.	128
<u>50</u>	AUC for all prognostic indices regarding prediction of one year shunt patency.	129



Introduction





Aim of the Work





Review of Literature

